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ABSTRACT 
Objectives To validate the educational needs assessment tool (The ENAT) as a generic tool for 
assessing the educational needs of patients with rheumatic diseases in European Countries. 
Methods A convenience sample of patients from seven European countries was included, comprising 
the following diagnostic groups: ankylosing spondylitis (AS), psoriatic arthritis (PsA), systemic 
sclerosis (SSc), systemic lupus erythematosus (SLE), osteoarthritis (OA) and fibromyalgia syndrome 
(FMS). Translated versions of the ENAT were completed through surveys in each country. Rasch 
analysis was used to assess the construct validity of the adapted ENATs including differential item 
functioning by culture (cross-cultural DIF). Initially, the data from each country and diagnostic group 
were fitted to the Rasch model separately, and then the pooled data from each diagnostic group. 
Results The sample comprised 3015 patients, the majority, 1996 (66.2%) were women. Patient 
characteristics (stratified by diagnostic group) were comparable across countries except the 
educational background, which was variable. In most occasions, the 39-item ENAT deviated 
significantly from the Rasch model expectations (item-trait interaction 2 p<0.05). After correction 
for local dependency (grouping the items into seven domains and analysing them as "testlets"), fit to 
the model was satisfied (item-trait interaction 2 p>0.18) in all pooled disease group datasets except 
OA (2=99.91; p=0.002). The internal consistency in each group was high (Person Separation Index 
above 0.90). There was no significant DIF by person characteristics. Cross-cultural DIF was found in 
some items, which required adjustments. Subsequently, interval-level scales were calibrated, to 
enable transformation of ENAT scores when required.  
Conclusions The adapted ENAT is a valid tool with high internal consistency, providing accurate 
estimation of the educational needs of people with rheumatic diseases. Cross-cultural comparison of 
educational needs is now possible. 
. 
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Introduction  
Patient education should be an integral part of the management of rheumatic diseases.1-4 It is an 
interactive process between patients and health care professionals aimed at enabling patients to 
participate actively in their health care, strengthen their ability to manage symptoms and treatment, 
improve coping strategies and increase self-care abilities.5-7 It is important for health professionals to 
assess patient’s experiential knowledge about arthritis, their own expectations, educational needs 
and priorities before providing education. This will help to tailor education to individual needs, and 
promote shared decision-making, which are important in helping patients to manage their illness and 
maintain quality of life.8-10 
The educational needs assessment tool (ENAT) is a self-completed questionnaire, which allows 
patients with arthritis to prioritise their educational needs. If completed immediately before the 
consultation, the health professional is able to provide education based on the patient’s immediate 
priorities.11 It was developed by people with arthritis and their practitioners in the UK, and comprises 
39 items grouped into seven domains: managing pain (six items), movement (five items), feelings 
(four items), disease process (seven items), treatments (seven items), self-help measures (six items) 
and support systems (four items). Items are completed by the use of Likert scales ranging from 1 - 
’not important at all’ to 5 - ’extremely important‘. Early research found the ENAT to be acceptable to 
patients, easy to complete and having good test-retest reliability.11 The ENAT was further validated 
using Rasch analysis where it demonstrated a good fit to the Rasch model indicating a good construct 
validity and invariance to gender, age, disease duration and educational background.12 In order to 
extend its use to European countries and allow multinational comparison of educational needs of 
people with rheumatoid arthritis (RA), the ENAT was adapted for use in six other European countries; 
(Finland, The Netherlands, Norway, Portugal, Spain and Sweden) and was found to have cross-
cultural validity and invariance with some adjustments required for The Netherlands.13 Since the 
ENAT was intended to be a generic measure across rheumatic diseases, further work was undertaken 
in the UK to validate it in other major rheumatic diseases, that is ankylosing spondylitis (AS), psoriatic 
 4 
arthritis (PsA), systemic sclerosis (SSc), systemic lupus erythematosus (SLE), osteoarthritis (OA) and 
fibromyalgia syndrome (FMS).14 The aim of this study was to validate the ENAT as a generic tool with 
which to assess the educational needs of patients with rheumatic diseases in seven European 
countries. 
Methods  
Study design and patients 
This was a multicentre European collaborative study, funded by a research grant from European 
League Against Rheumatism (EULAR grant reference HPR011). It followed a cross-sectional survey 
design, requiring patient completion of the translated versions of the ENAT on one occasion and 
testing its cross-cultural validity using Rasch analysis. The study was led from the University of Leeds 
(UK) and involved seven European countries; Austria, Finland, The Netherlands, Norway, Portugal, 
Spain and Sweden. The methods were set out a priori in the study protocol (unpublished), and all 
collaborating centres obtained ethical approvals from their respective countries before undertaking 
the study. 
Convenience sampling was used to recruit patients from rheumatology outpatient clinics, day units, 
in-patient wards, databases, rehabilitation centres and/or from the community in the collaborating 
countries. The inclusion criteria were: (i) positive diagnosis of the target diseases (AS, PsA, SSc, SLE, 
OA or FMS) (ii) aged 18 years or above and (iii) willingness and ability to complete and return a 
questionnaire. The exclusion criteria were (i) inability to complete the ENAT unaided, (ii) having more 
than one form of rheumatic disease and (iii) having mental impairment.  
Measures 
The cross-cultural adaptation of the original (English) ENAT into the respective European languages 
was previously undertaken in RA,13 using an established process for cross-cultural adaptation of self-
report measures.15 The process involved five steps: (1) forward translation - from English into the 
target language, (2) synthesis of the translations; (3) back (blind) translation into the original (English) 
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language; (4) expert committee review which decided on equivalence between the source and target 
versions; and (5) test of the pre-final version - testing the "adapted" version with 30 patients. Due to 
inclusion of different diagnostic groups in the present study, it was agreed in the set-up meeting, to 
use the term ‘rheumatic disease’ for inflammatory arthritis and connective tissue disease groups, and 
keep ‘arthritis’ for people with OA. However, in other countries such as Portugal and Spain, the term 
"rheumatic disease" was used for all diseases, including OA. This is because in those countries the 
term "arthritis" implies the presence on synovitis/effusion; and OA is also a rheumatic disease and 
recognised by patients and health care professionals as such (albeit degenerative rather than 
inflammatory).  
The translated versions of the ENAT were given to patients in their respective countries to complete 
as postal surveys or before their clinic consultations or at the beginning of their rehabilitation 
programme. The ENATs were anonymous but contained patients’ demographical data such as 
gender, age, educational background and self-reported disease duration. Once completed, the ENATs 
were sent by post to the University of Leeds for analysis. The ENAT data were then entered into a 
database (IBM SPSS, version 19)16 and were subjected into Rasch analysis using RUMM202017 
software. 
Data analysis  
Rasch analysis is a mathematical modelling technique used to assess properties of outcome 
measures against a measurement model developed by the Danish mathematician Georg Rasch.18 The 
Rasch model provides a formal representation of fundamental measurement, and in Rasch analysis 
the observed data from questionnaires are measured against the Rasch model to assess how well 
they ’fit‘ the model. Fit to the model implies a criterion-related construct validity, reliability and 
statistical sufficiency.19-21 Further details of Rasch Analysis tests of fit are published elsewhere.22 
All ENAT items were assessed individually and collectively for fit to the model, testing for the 
assumption of local independence of items and the overall fit. Local independence means that items 
that fit the Rasch model are expected to be independent of each other, that is, there should not be 
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any correlation between two items after the effect of the underlying construct is conditioned out.23 
In the analysis, the items that were found to be locally dependent (a correlation of ±0.3 being the 
threshold for local dependency)24 were combined into a subtest and treated as a ’testlet‘, which is 
defined as a subset of items that is treated as a measurement unit in test construction, 
administration and/or scoring.25  
The data from each diagnostic group from each country were tested for the overall fit to the Rasch 
model and differential item functioning (DIF) by gender, age, disease duration and educational 
background. DIF occurs when two groups of equal ability levels are not equally able to correctly 
answer an item. If the factor leading to DIF is not part of the construct being tested, then the item is 
biased, that is,  observed scores should depend only on latent construct scores, and not on group 
membership or occasion.26-29 It is important to identify the biased items, so that adjustments can be 
made, which may sometimes involve discarding the item.29 To allow for group comparisons, age and 
disease duration, which are continuous data, were converted into categorical data by splitting at the 
medians. Educational background was simply categorised as: those with only compulsory (basic) 
education and those with further education. Group comparisons tested the assumption of invariance 
(absence of DIF) of the ENAT across all patient subgroups, that is  age groups, gender, disease 
duration and educational background. Following country-specific analyses, the data was pooled in 
each disease group and fit to the Rasch model was assessed. The pooled data were additionally 
tested for DIF by culture (cross-cultural bias). Where cross-cultural DIF was found, a post-hoc (Tukey 
test) was performed to assess where the significant difference lies, and the biased items were 
adjusted for the using the method described by Tennant et al29  and Brodersen et al.28 
The overall fit statistics are reported as 2 probability, where p-value is expected to be non-
significant for adequate fit to the model. In most analyses, the p-values were Bonferroni-adjusted to 
the level (ie, p = 0.05/number of tests carried out), to avoid type I errors due to multiple testing.30 
Reliability is reported as Person Separation Index (PSI), which estimates the internal consistency of 
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the scale equivalent to Cronbach's , only using the logit value as opposed to the raw score in the 
same formulae. A minimum value of 0.7 is required for group use and 0.85 for individual use.22  
Following fit to the Rasch model, the test of strict unidimensionality of the ENAT was conducted 
using the t-test method suggested by Smith,31 where unidimensionality is confirmed if less than 5% of 
independent t-tests on the latent estimates derived from two independent sets of items lie outside 
the ±1.96 range. The ENATs were then calibrated into an interval-level scale to allow for Rasch-
transformation of the ordinal data into interval level data when required.32 
Results  
A total of 3219 patients were recruited in this study. In all, 74 patients with undifferentiated 
spondyloarthropathy from Sweden and 130 with RA from Austria were excluded from the analysis, as 
these diagnostic groups were not included in the protocol. This meant that data from 3015 patients 
were analysed. Patient characteristics (stratified by diagnostic group) were comparable across 
countries except for educational background, which was variable. Table 1 summarises the country-
specific gender distribution, mean age, disease duration, educational background and the availability 
of data in each diagnostic group.  
Table 1 Sample characteristics by country 
Country Gender Age Disease 
duration 
Educational 
background 
Diagnostic groups  
 Female (%) Mean (SD) Mean (SD) Only basic 
education (%) 
AS PsA SSc SLE OA FMS Sample 
size (N) 
Austria 96 (55.8) 55.3 (11.1) 12.5 (10.6) 86 (51.5) - 125 - - 47 - 172 
Finland 368 (82.1) 53.2 (12.1) 12.2 (10.3) 115 (24.6) 84 86 171 - - 108 449 
The 
Netherlands 
368 (69.0) 53.3 (15.1) 13.8 (11.9) 37 (6.7) 85 112 103 126 126 - 552 
Norway 398 (68.9) 51.9 (12.0) 10.6 (9.9) 143 (24.4) 146 147 - - 149 144 586 
Portugal 362 (64.0) 50.8 (15.3) 13.0 (10.1) 228 (42.1) 121 132 28 146 88 53 568 
Spain 321 (63.8) 48.2 (13.8) 12.6 (9.8) 180 (37.0) 141 124 59 99 23 57 503 
Sweden 83 (44.9) 55.8 (12.5) 21.0 (12.1) 55 (29.7) 102 83 - - - - 185 
Pooled 1996 (66.2) 52.6 (13.1) 13.7 (10.7) 844.0 (28.0%) 679 809 361 371 433 362 3015 
AS,Ankylosing spondylitis; FMS, fibromyalgia syndrome; OA, Osteoarthritis; PsA, Psoriatic arthritis; SLE, Systemic lupus erythematosus; SSc, 
Systemic sclerosis.  
The data from each diagnostic group and country were fitted to the Rasch model separately (Table 2) 
and then they were pooled into diagnostic group datasets (Table 3). In most diagnostic groups (AS, 
PsA, SSc and SLE), the five response categories (Likert scales) were found to work as expected. The 
 8 
preliminary analysis of the individual 39 items resulted in significant deviation from the Rasch model, 
that is,  the p values of the 2 interaction were significant in all disease groups (Table 2: Analysis 1). 
Lack of fit to the model was caused by significant correlations of items within each domains (a 
residual correlation of ±0.3 being the threshold for local dependency).24 Correction for local 
dependency involved grouping the 39 items into their respective seven domains (ie, pain, movement, 
feelings, disease process, treatments, self-help and support) and scoring the ENAT as a ‘seven-testlet’ 
scale. Fit to the Rasch model was achieved in all country–specific data following correction for local 
dependency with the exception of the OA disease group from Portugal. In all country-specific 
datasets, the internal consistency was high (PSI>0.88 - PSI of 0.7 is required for group use) (Table 2: 
Analysis 2). These results mean that the domain (subscale) scores of the ENAT can be summed up to 
give a total score. 
Table 2 Country-specific results of Rasch analysis 
   
Item Fit 
Residual 
Person Fit 
Residual Chi Square Interaction   
Proportion of 
significant (95% CI)   Analysis Mean SD Mean SD Value (df) p PSI N 
Norway A
S 
Analysis 1 0.315 1.643 -0.238 1.186 163.045 (78) 0.001 0.97 142  
Analysis 2 0.189 0.87 -0.322 1.131 12.005 (14) 0.606 0.947 142 0.085 (0.049, 0.120) 
Finland A
S 
Analysis 1 0.418 1.197 -0.214 2.136 38.262 (39) 0.503 0.969 85  
Analysis 2 0.421 0.612 -0.237 1.102 8.780 (7) 0.269 0.927 85 0.094 (0.048, 0.140) 
Sweden A
S 
Analysis 1 0.379 0.991 -0.25 2.136 121.031 (78) 0.001 0.901 102  
Analysis 2 0.38 0.624 -0.277 1.19 6.818 (7) 0.448 0.623 102 0.040 (-0.003, 0.082) 
The 
Netherlands A
S 
Analysis 1 0.355 1.362 -0.261 2.208 50.328 (39) 0.106 0.978 82  
Analysis 2 0.481 0.998 -0.25 1.167 4.281 (7) 0.747 0.947 82 0.123 (0.076, 0.171) 
Portugal A
S 
Analysis 1 0.421 1.353 -0.662 2.946 54.546 (39) 0.502 0.966 121  
Analysis 2 0.372 0.291 -0.364 1.205 6.021 (7) 0.537 0.902 121 0.057 (0.019, 0.097) 
Spain A
S 
Analysis 1 0.277 1.947 -0.289 2.199 184.606 (78) 0.001 0.976 129  
Analysis 2 0.301 1.116 -0.345 1.175 12.970 (14) 0.529 0.953 128 0.070 (0.033, 0.108) 
Austria  P
sA
 Analysis 1 0.286 1.147 -0.382 2.041 97.313 (78) 0.068 0.967 123  
Analysis 2 0.611 1.021 -0.363 1.284 11.541 (14) 0.643 0.931 119 0.076 (0.036, 0.115) 
Norway P
sA
 Analysis 1 0.379 1.258 -0.08 1.671 156.851 (78) <0.001 0.969 142  
Analysis 2 0.442 0.654 -0.237 1.023 10.012 (14) 0.761 0.933 142 0.056 (0.021, 0.093) 
Finland P
sA
 Analysis 1 0.297 1.121 -0.159 2.032 55.614 (39)  0.041 0.977 82  
Analysis 2 0.138 0.88 -0.256 1.041 6.044 (7) 0.535 0.954 82 0.061 (0.014, 0.108) 
Sweden P
sA
 Analysis 1 0.432 1.003 -0.269 2.169 51.271 (39) 0.09 0.96 82  
Analysis 2 0.519 0.617 -0.39 1.281 10.698 (7) 0.152 0.91 82 0.074 (0.027, 0.122) 
The P
sA
 
Analysis 1 0.609 1.708 -0.233 2.301 77.078 (39) <0.001 0.974 110  
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Netherlands Analysis 2 0.805 1.316 -0.255 1.181 6.117 (7) 0.526 0.936 108 0.093 (0.051, 0.134) 
Portugal P
sA
 Analysis 1 0.379 1.862 -0.679 2.986 162.025 (78) <0.001 0.983 126  
Analysis 2 0.438 1.119 -0.499 1.357 12.743 (14)  0.547 0.959 126 0.065 (0.026, 0.103) 
Spain P
sA
 Analysis 1 0.544 1.761 -0.169 2.166 90.500 (39) <0.001 0.974 115  
Analysis 2 0.44 1.154 -0.301 1.125 5.473 (7) 0.602 0.954 114 0.070 (0.030, 0110) 
Finland SS
c Analysis 1 0.532 1.596 -0.476 2.613 126.607 (78) <0.001 0.969 167  
Analysis 2 0.297 0.897 -0.427 1.32 17.624 (14) 0.224 0.929 167 0.083 (0.051, 0.117) 
The 
Netherlands S
Sc
 Analysis 1 0.453 1.59 -0.188 2.154 89.627 (39) <0.001 0.978 99  
Analysis 2 0.836 0.745 -0.248 1.248 6.862 (7) 0.443 0.951 99 0.040 (-0.003, 0.083) 
Portugal SS
c Analysis 1 0.38 0.798 0.055 1.999 22.310 (39) 0.985 0.977 28  
Analysis 2 0.645 0.529 -0.011 0.975 3.037 (7) 0.882 0.938 28 0.107 (0.026, 0.188) 
Spain SS
c Analysis 1 0.291 1.146 -0.052 1.748 52.626 (39) 0.071 0.98 39  
Analysis 2 0.475 0.859 -0.057 0.881 4.891 (7) 0.673 0.969 39 0.051 (-0.017, 0.120) 
The 
Netherlands S
LE
 Analysis 1 0.511 1.818 -0.329 2.626 112.920 (39) <0.001 0.970 123  
Analysis 2 0.397 1.176 -0.346 1.244 5.862 (7) 0.556 0.939 123 0.059 (0.020, 0.098) 
Portugal SL
E Analysis 1 0.182 1.264 -0.426 2.405 164.349 (78) <0.001 0.973 142  
Analysis 2 0.416 0.957 -0.423 1.317 11.591 (14) 0.639 0.936 142 0.049 (0.013, 0.085) 
Spain SL
E Analysis 1 0.508 1.542 -0.020 1.700 104.037 (39) <0.001 0.964 95  
Analysis 2 0.494 0.651 -0.233 1.053 19.581 0.144 0.933 95 0.055 (0.010, 0.100) 
Finland 
FM
S Analysis 1 0.262 1.401 -0.192 1.824 57.954 (39) 0.026 0.969 105  
Analysis 2 0.324 0.879 -0.171 0.953 3.438 (7) 0.842 0.936 105 0.059 (0.017, 0.101) 
Norway 
FM
S Analysis 1 0.267 1.612 -0.107 1.529 126.819 (78) <0.001 0.96 133  
Analysis 2 0.222 0.736 -0.257 1.009 12.144 (14) 0.595 0.928 133 0.045 (0.008, 0.082) 
Portugal 
FM
S Analysis 1 0.527 0.725 -0.227 2.635 73.211 (39) <0.001 0.99 41  
Analysis 2 0.687 0.589 -0.128 1.201 7.339 (7) 0.394 0.984 41 0.073 (0.006, 0.140) 
Spain 
FM
S Analysis 1 0.388 1.518 0.166 1.548 120.972 (39) <0.001 0.971 50  
Analysis 2 0.195 0.640 -0.105 0.706 8.157 (7) 0.319 0.946 50 0.040 (-0.020, 0.100) 
Austria OA O
A
 Analysis 1 0.147 0.827 -0.122 1.794 61.360 (39) 0.013 0.951 47  
Analysis 2 0.55 1.136 -0.224 1.141 12.759 (7) 0.078 0.886 47 0.085 (0.023, 0147) 
The 
Netherlands  O
A
 Analysis 1 0.431 1.497 -0.257 2.42 333.770 (273) 0.007 0.976 121  
Analysis 2 0.294 0.784 -0.284 1.154 5.692 (7) 0.576 0.947 121 0.041 (0.003, 0.081) 
Norway O
A
 Analysis 1 0.227 1.489 -0.255 1.72 113.076 (78) 0.006 0.97 138  
Analysis 2 0.395 0.811 -0.296 1.103 16.310 (14) 0.295 0.947 138 0.044 (0.007, 0.081) 
Portugal  O
A
 Analysis 1 -0.427 1.832 -1.885 3.593 78.487 (39) <0.001 0.992 77  
Analysis 2 0.493  1.710  
-
0.452  
1.350  14.765 (7)  0.039  0.987  77 0.064 (0.016, 0.114) 
Spain O
A
 Analysis 1 0.284 0.8 0.143 2.329 70.762 0.001 0.95 23  
Analysis 2 0.272 0.543 -0.121 0.967 7.426 (7) 0.386 0.89 23 0.130 (0.041, 0.220) 
Expected values for a perfect 
model fit 
0 1 0 1  > 0.05 > 0.70  
Lower-bound CI 
<0.05 
Analysis 1=Rasch analysis of the ENAT as a 39-item scale; Analysis 2=Rasch analysis of the ENAT as a 7-domain scale. AS,Ankylosing 
spondylitis; DF, degrees of freedom, ENAT, educational needs assessment tool; FMS, fibromyalgia syndrome; OA, Osteoarthritis; P, 2 
probability, (significant p, item misfit); PsA, Psoriatic arthritis; PSI, Person Separation Index; SLE, Systemic lupus erythematosus; SSc, 
Systemic sclerosis. 
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In each pooled (diagnostic-specific) data, fit to Rasch model was also satisfied, with the exception of 
the OA dataset (Table 3). In all pooled analyses, person separation index (PSI) was greater than 0.93 
indicating an excellent reliability (internal consistency) for both group and individual uses. Strict 
unidimensionality of the overall scale was confirmed in all disease groups except in the AS and PsA 
diagnostic groups in which the proportions of significant t-tests (95%CI) were 0.074 (0.058, 0.092) 
and 0.071 (0.056, 0.086) respectively, indicating a small degree of multidimensionality. Post-hoc 
analyses that followed later (Table 4), suggested this to be caused by cross-cultural DIF. 
Table 3 Diagnostic group (pooled datasets) results of Rasch analysis 
 Diagno
stic 
group   
Item Fit 
Residual 
Person Fit 
Residual Chi Square Interaction 
PSI 
   Proportion of 
significant T-Tests 
(95% CI)   Analysis Mean SD Mean SD Value (df) p N 
Pooled 
AS 
Analysis 1 0.563 2.959 -0.557 2.584 683.931 (351) <0.001 0.972 661   
Analysis 2 0.314 0.905 -0.493 1.347 72.674 (63) 0.189 0.938 660 
0.074 (0.058, 
0.092) 
Pooled 
PsA 
Analysis 1 0.957 3.096 -0.499 2.517 787.691 (351) <0.001 0.975 780   
Analysis 2 0.575 1.218 -0.445 1.279 70.460 (63) 0.242 0.944 777 
0.071 (0.056, 
0.086) 
Pooled 
SSc 
Analysis 1 0.699 2.232 -0.532 2.634 527.415 (351) <0.001 0.976 333   
Analysis 2 0.664 1.270 -0.384 1.262 43.006 (35) 0.166 0.949 333 
0.051 (0.026, 
0.074) 
Pooled 
SLE 
Analysis 1 0.560 2.559 -0.497 2.551 476.407 (234) <0.001 0.969 360   
Analysis 2 0.514 1.166 -0.421 1.298 39.817 (42) 0.567 0.932 358 
0.051 (0.028, 
0.074) 
Pooled 
FMS 
Analysis 1 0.607 2.482 -0.251 1.972 450.441 (273) <0.001 0.972 329   
Analysis 2 0.378 0.986 -0.257 1.016 47.060 (42) 0.273 0.950 329 
0.025 (0.001, 
0.048) 
Pooled 
OA 
Analysis 1 0.775 2.689 -0.701 3.022 709.905 (351) <0.001 0.976 430  
Analysis 2 0.406 1.845 -0.434 1.273 99.906 (63) 0.002 0.950 429 Misfit 
Expected values for a 
perfect model fit 
0 1 0 1  > 0.05 > 0.70  
Lower-bound CI 
<0.05 
Analysis 1=Rasch analysis of the ENAT as a 39-item scale; Analysis 2=Rasch analysis of the ENAT as a 7-domain scale. 
AS,Ankylosing spondylitis; DF, degrees of freedom, ENAT, educational needs assessment tool; FMS, fibromyalgia syndrome; 
OA, Osteoarthritis; P, 2 probability, (significant p, item misfit); PsA, Psoriatic arthritis; PSI, Person Separation Index; SLE, 
Systemic lupus erythematosus; SSc, Systemic sclerosis 
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A formal assessment of invariance (DIF analysis) was performed in the diagnostic groups that 
satisfied the Rasch model requirements (AS, PsA, SSc, SLE and FMS). There was no significant DIF by 
gender, age, disease duration or educational background in the country specific datasets. This 
suggests that the ENAT is not biased by person characteristics. However, in the pooled datasets, DIF 
by culture was detected across the diagnostic groups indicating a cross-cultural bias especially in the 
PsA disease group (Table 4).  
Table 4  Domains adjusted for cross-cultural DIF 
 AS PsA SSc SLE FMS 
Pain X X S S S 
Movements S S S X S 
Feelings S S S S S 
Disease process S X S S S 
Treatments S X X  X  S 
Self-help S X S S S 
Support X X X  S S 
AS, Ankylosing spondylitis; DIF, differential item functioning; FMS, fibromyalgia syndrome; PsA, Psoriatic arthritis; S, cross-cultural 
invariance satisfied; SLE, Systemic lupus erythematosus; SSc, Systemic sclerosis; X, lack of cross-cultural invariance. 
 
Adjustments were made in the biased items to account for the cross-cultural DIF. This involved 
‘splitting’ the biased item into two; where one is rendered unique for the affected country and the 
other for the rest of the countries. For example in the AS disease group (Table 5), there are two pain 
testlets, one unique for Norway and the other for the rest of the countries. The unsplit (pure) items 
act as links in the calibration of the scale thus discounting the cross-cultural bias.28,29 Following this 
adjustment, the resulting testlets were found to adequately fit the model (Table 5). This means that 
the ENAT can be used in its present form within each country without any need for adjustments. 
However, when data across countries are being pooled or compared, then adjustment for cross-
cultural DIF will be required. We have calibrated DIF-adjusted interval-level scales for this purpose 
(see online supplementary tables 1-14). 
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Table 5  Fit statistics after adjustment for cross-cultural DIF in the affected testlets 
Domain Testlet Location SE 
Fit 
Residuals 
X
2
 P 
AS       
Pain Pain-Norway -0.15 0.03 -1.13 7.76 0.56 
Pain- Others -0.01 0.01 0.47 14.70 0.10 
Movement Movement 0.07 0.01 -0.80 10.73 0.29 
Feelings Feelings 0.04 0.01 -0.18 16.08 0.07 
Disease process Disease process -0.14 0.01 0.21 8.11 0.52 
Treatments Treatments 0.04 0.01 0.83 7.97 0.54 
Self-Help Self-Help -0.10 0.01 2.04 5.59 0.78 
Support Support –The Netherlands 0.15 0.04 -0.96 7.18 0.62 
Support - Others 0.09 0.01 0.70 10.02 0.35 
PsA       
Pain Pain - Austria -0.06 0.03 -1.07 6.73 0.46 
Pain - Norway -0.70 0.04 0.23 6.54 0.48 
Pain – The Netherlands 0.13 0.03 -0.09 5.69 0.58 
 Pain - Others 0.08 0.02 -0.57 5.65 0.58 
Movement Movement 0.20 0.01 2.51 8.28 0.31 
Feelings Feelings 0.16 0.01 2.45 4.09 0.77 
Disease process Disease process - Finland -0.15 0.04 -1.93 4.71 0.70 
Disease process - Others -0.13 0.01 -0.11 4.99 0.66 
Treatments Treatments - The Netherlands -0.08 0.03 0.77 8.07 0.33 
Treatments- Sweden -0.05 0.03 1.35 5.09 0.65 
 Treatments - Others 0.14 0.01 -0.27 7.72 0.36 
Self-Help Self-Help - The Netherlands -0.22 0.03 2.54 17.90 0.01 
Self-Help - Portugal 0.16 0.03 0.38 3.55 0.83 
Self-Help - Others -0.05 0.01 0.37 9.73 0.20 
Support Support - Austria 0.49 0.03 1.37 4.74 0.69 
Support- Finland -0.40 0.05 -0.93 6.53 0.48 
Support - Portugal 0.21 0.03 0.87 5.68 0.58 
 Support - Others 0.25 0.02 0.44 8.69 0.28 
SSc       
Pain Pain 0.06 0.02 0.17 6.93 0.23 
Movements Movements 0.12 0.02 -0.99 8.34 0.14 
Feelings Feelings 0.09 0.02 1.79 3.37 0.64 
Disease process Disease process -0.21 0.02 -0.02 10.97 0.05 
Treatments Treatments- The Netherlands -0.06 0.03 1.96 3.50 0.62 
Treatments-Others 0.03 0.02 0.74 5.61 0.35 
Self-Help Self-Help -0.16 0.02 0.77 4.13 0.53 
Support Support - The Netherlands 0.22 0.04 1.23 3.62 0.61 
Support - Others -0.09 0.03 1.28 10.51 0.06 
SLE       
Pain Pain 0.01 0.02 -0.13 5.31 0.50 
Movement Movements-Spain 0.03 0.03 -0.43 4.41 0.62 
Movements - Others 0.06 0.02 0.05 2.28 0.89 
Feelings Feelings -0.04 0.02 2.16 5.56 0.47 
Disease process Disease process -0.18 0.01 -0.60 12.62 0.05 
Treatments Treatments - Spain 0.18 0.02 0.27 4.02 0.67 
Treatments - Others -0.02 0.02 0.75 4.23 0.65 
Self-Help Self-Help -0.12 0.02 0.18 6.20 0.40 
Support Support 0.08 0.02 2.05 9.22 0.16 
FMS       
Pain Pain -0.04 0.02 0.40 5.38 0.37 
Movements Movements -0.04 0.02 0.68 3.56 0.61 
Feelings Feelings -0.05 0.02 0.79 3.20 0.67 
Disease process Disease process -0.13 0.02 -1.24 6.88 0.23 
Treatments Treatments 0.28 0.02 1.96 5.52 0.36 
Self-Help Self-Help -0.08 0.02 0.13 8.72 0.12 
Support Support - The Netherlands 0.06 0.02 -0.14 6.12 0.29 
SE = Standard error, P = Bonferroni-adjusted Χ
2 
probability, (non-significant P = Fit to the model), 
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Following adjustment to the cross-cultural DIF (in the AS, PsA, SSc and SLE diagnostic groups), the 
raw ENAT domain scores were mapped against the corresponding Rasch-transformed scores (based 
in logits) and were linearly transformed to calibrate interval-level, DIF-adjusted scales of the same 
range (see online supplementary tables 1-14). The details on the use and scoring of the ENAT are 
given in the online supplementary material.  
Discussion  
This study set out to test the cross-cultural validity of the ENAT as a generic measure of educational 
needs in people with AS, PsA, SSc, SLE, OA and FMS in different European countries. The results 
indicate that, following its adaptation; the ENAT maintained its validity in each disease group that 
was tested (with limitations in OA). The implications of the results in terms of clinical use and 
measurement aspects are set out below.  
In the clinical practice, the ENAT is used as a template/checklist to assess what are the most 
important educational/informational needs from the patient’s point of view. Patients using the ENAT 
have consistently found it easy to complete and effective in identifying their needs and raise 
questions which they would not have otherwise considered.12,33 This information, along with the 
clinicians’ insight of what the patient needs to know, allows the provision of timely and meaningful 
education tailored to the needs of each individual patient. When used in this way (for clinical 
purposes), the ENAT does not need scoring. However, when used as an outcome measure or for 
comparison of educational needs across groups, then the measurement properties of the ENAT need 
to be considered. 
From the measurement point of view, the adapted ENAT has been shown to fit the Rasch model, a 
requirement for questionnaires with items that are intended to be summed together to provide a 
total score.22 While the level of ‘educational needs’ represented by each domain may differ across 
disease groups, fit to the Rasch model confirms the validity of the ‘educational needs’ construct as 
measured by the ENAT in each disease group (with limitations in OA). Local dependency was the 
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main issue affecting measurement properties of the ENAT. Since the items within a domain are by 
definition related, it was not surprising to find significant item-item correlations within respective 
domains. This was also seen in a similar study in RA.13 Correction for this may involve removing the 
redundant items or grouping all the locally-dependent items into a testlet (hence scoring them as a 
unit). We used the ‘testlet’ approach as it helps to retain the clinically relevant items, yet meeting the 
measurement requirements of the scale. This approach to scoring is similar to that used in other 
scales such as the HAQ34 and the HADs.35 
While the ENAT was invariant to person characteristics, some items worked differently in some 
countries especially in the OA and SpA disease groups. Therefore, when the data across different 
countries are combined/compared, adjustments will be required (cross-cultural comparisons are not 
possible in OA). We have calibrated interval-level scales (see online supplementary tables 1-14), 
which are adjusted to cross-cultural DIF, thus enabling accurate estimation of educational needs and 
comparison across the countries when required. Previous estimation of educational needs for people 
with arthritis used the ENAT ordinal measures and non-parametric methods,33,36 which can be 
limiting if other outcome measures have to be taken into account in the analyses such as in linear 
regression models. Conversion of the ordinal measures into interval levels (Rasch-transformed 
values) enables the use of ENAT scores in parametric analyses,32 alongside other measures, given 
adequate sample sizes and normal distribution. Recently, Rasch-transformed scores from the ENAT 
have been used to assess to its correlation with disease activity and disability in RA and PsA.37  
While the ENAT remains a valid country-specific measure of education needs for people with OA, 
strong conclusions cannot be made about its cross-cultural validity, which warrants further research. 
One of the reasons for the lack of fit in this group may be the inherent heterogeneous nature of OA, 
where educational needs of patients with hand OA may be different from those of patients with hip 
or knee OA. This implies that when assessing the educational needs of people with OA, the data from 
different countries should not be pooled until their cross-cultural validity has been established.  
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This study has four main limitations. First, in most countries the data were collected from limited 
sources and therefore not representative of the countries involved. However, this does not affect the 
conclusions of this tool validation research, as this research did not set out to assess the educational 
needs but rather to determine the validity of the ENAT and its psychometric properties following its 
adaptation. Second, not all disease groups were represented in each country. Therefore the results 
apply only in the available disease groups. Third, being a cross-sectional study, the ENAT’s stability to 
change has not been established. However, given the nature of needs assessment, it is difficult to 
establish ‘stability’ as the educational needs are dynamic. Lastly, due to developments in the 
understanding of rheumatic diseases and their management, coupled by developments in 
information technology, the ENAT items do not cover everything there is to know about rheumatic 
diseases. However the ENAT domains remain relevant in assessing patient priorities and the items 
are formulated in a way that is open to change. Future developments will address this limitation by 
creating item banking for computerised adaptive assessment. This means having more and ‘dynamic’ 
items but delivering few targeted items according to need.  
The instructions of how the ENAT is used and scored, are provided in the online supplementary 
material, and the different versions of the ENAT can be obtained by writing to the Psychometric 
Laboratory at the University of Leeds 
(http://www.leeds.ac.uk/medicine/rehabmed/psychometric/index1.htm) or the corresponding 
author.  
Conclusion  
This study has established that the ENAT is a valid and a reliable tool, providing an accurate measure 
of educational needs for people with rheumatic diseases. While clinical use of the ENAT as a simple 
checklist does not require scoring, its interval-level scale provides estimates that can be used 
alongside other variables in parametric analyses. In addition, a facility is available for cross-cultural 
comparisons when required. Further research is required in its use in electronic formats and 
development as a computerised adaptive assessment.  
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